Combination of apolipoprotein A1-Modi liposome-doxorubicin with autophagy inhibitors overcame drug resistance in vitro

Journal of Pharmaceutical Sciences

Volumn 103, Issue 12, 2014, Pages 3994-4004

  Wang, Baolong ^a   Feng, Duo ^b   Han, Lei ^a   Fan, Jiajun ^a   Zhang, Xiaozhe ^c   Wang, Xin ^a   Ye, Li ^a   Shi, Xunlong ^a   Feng, Meiqing ^a  

^a FUDAN UNIVERSITY   (China)

^b The 6th Affiliated Hospital of Shenzhen University Health Science Center   (China)

^c EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Apo Lipodox; Apoptosis; Autophagy; Chemotherapy; Multidrug resistance

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; APOLIPOPROTEIN A1; CHLOROQUINE; DOXORUBICIN; LIPOSOME; MACROGOL DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL LINE; DRUG ACCUMULATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; KB CELL LINE; MULTIDRUG RESISTANCE; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; TUMOR CELL LINE;

APOLIPOPROTEIN A-I; AUTOPHAGY; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HEP G2 CELLS; HUMANS; KB CELLS; POLYETHYLENE GLYCOLS;

EID: 84915747829     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24216     Document Type: Article

References (41)

1. Thundimadathil J. 2012. Cancer treatment using peptides: Current therapies and future prospects. J Amino Acids 2012:967347.
2. Patil Y, Sadhukha T, Ma L, Panyam J. 2009. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 136(1):21-29.
3. Fares F, Ganem S, Hajouj T, Agai E. 2007. Development of a longacting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin β-subunit to the coding sequence of human erythropoietin. Endocrinology 148(10):5081-5087.
4. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. 2008. Multifunctional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 34(7):592-602.
5. Nguyen CB, Harris L, Szönyi É, Baughman SA, Hale VG, Dybdal NO, Sadick MD, Escandón E. 2000. Tissue disposition and pharmacokinetics of recombinant human nerve growth factor after acute and chronic subcutaneous administration in monkeys. Drug Metab Dispos 28(5):598-607.
6. Tria MA, Fusco M, Vantini G, Mariot R. 1994. Pharmacokinetics of nerve growth factor (NGF) following different routes of administration to adult rats. Exp Neurol 127(2):178-183.
7. Wang F, Wang Y-C, Dou S, Xiong M-H, Sun T-M, Wang J. 2011. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 5(5):3679-3692.
8. Lage H. 2006. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal ofmultidrug resistance. Curr Drug Target 7(7):813-821.
9. Takara K, Sakaeda T, Okumura K. 2006. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12(3):273-286.
10. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. 2011. Nanomedicine for targeted cancer therapy: Towards the overcoming of drug resistance. Drug Resist Update 14(3):150-163.
11. Cho K, Wang X, Nie S, Shin DM. 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14(5):1310-1316.
12. Riganti C, Voena C, Kopecka J, Corsetto PA, Montorfano G, Enrico E, Costamagna C, Rizzo AM, Ghigo D, Bosia A. 2011. Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells. Mol Pharm 8(3):683-700.
13. Markman M. 2006. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacother 7:469-474.
14. Lu Y, Low PS. 2012. Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev 54:675-693.
15. Kumar P, Zhang D-M, Degenhardt K, Chen Z-S. 2012. Autophagy and transporter-based multi-drug resistance. Cells 1(3):558-575.
16. Stavrovskaya A. 2000. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 65(1):95-106.
17. Shieh MJ, Hsu CY, Huang LY, Chen HY, Huang FH, Lai PS. 2011. Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. J Control Release 152(3):418-425.
18. Yin Q, Shen J, Zhang Z, Yu H, Chen L, Gu W, Li Y. 2013. Multifunctional nanoparticles improve therapeutic effect for breast cancer by simultaneously antagonizing multiple mechanisms of multidrug resistance. Biomacromolecules 14(7):2242-2252.
19. Wan XM, Zheng F, Zhang L, Miao YY, Man N, Wen LP. 2011. Autophagy-mediated chemosensitization by cysteamine in cancer cells. Int J Cancer 129(5):1087-1095.
20. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA. 2010. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 3(147):ra81.
21. Aredia F, Scovassi AI. 2013. Manipulation of autophagy in cancer cells: An innovative strategy to fight drug resistance. Future Med Chem 5(9):1009-1021.
22. Mizushima N. 2007. Autophagy: Process and function. Genes Dev 21(22):2861-2873.
23. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. 2010. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta 1806(2):220-229.
24. LiuL, Yang M, Kang R, Wang Z, Zhao Y, YuY, Xie M, Yin X, Livesey KM, Lotze MT, Tang D, Cao L. 2011. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 25(1):23-31.
25. Li Y, Zhu H, Zeng X, Fan J, Qian X, Wang S, Wang Z, Sun Y, Wang X, Wang W, Ju D. 2013. Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Mol Neurobiol 47(3):1000-1010.
26. Yuan Y, Wang W, Wang B, Zhu H, Zhang B, Feng M. 2013. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 21(4):367-374.
27. Wang B, Yuan Y, Han L, Ye L, Shi X, Feng M. 2014. Lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma. J Drug Target 22(1):76-85.
28. Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, Nel AE. 2010. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 4(8):4539-4550.
29. Patil YB, Swaminathan SK, Sadhukha T, Ma L, Panyam J. 2010. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 31(2):358-365.
30. Dong X, Mattingly CA, Tseng MT, Cho MJ, Liu Y, Adams VR, Mumper RJ. 2009. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 69(9):3918-3926.
31. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG. 2008. Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. AntiCancer Drug 19(2):183-188.
32. Rensen PC, de Vrueh RL, Kuiper J, Bijsterbosch MK, Biessen EA, van Berkel TJ. 2001. Recombinant lipoproteins: Lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47(2):251-276.
33. Oda MN, Hargreaves PL, Beckstead JA, Redmond KA, van Antwerpen R, Ryan RO. 2006. Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B. J Lipid Res 47(2):260-267.
34. Feng M, Cai Q, Huang H, Zhou P. 2008. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 68(3):688-693.
35. Silva RGD, Huang R, Morris J, Fang J, Gracheva EO, Ren G, Kontush A, Jerome WG, Rye K-A, Davidson WS. 2008. Structure of apolipoprotein AI in spherical high density lipoproteins of different sizes. Proc Natl Acad Sci 105(34):12176-12181.
36. Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q. 2012. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy. Biomaterials 33:8893-8905.
37. Shao Y, Gao Z, Marks PA, Jiang X. 2004. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci 101(52):18030-18035.
38. Mathew R, White E. 2011. Autophagy in tumorigenesis and energy metabolism: Friend by day, foe by night. Curr Opin Genet Dev 21(1):113-119.
39. Rabinowitz JD, White E. 2010. Autophagy and metabolism. Science 330(6009):1344-1348.
40. Wu D, Ma S, Sui F, Zhang C, Yin L, Lu H. 2008. Reversal of CQ11, a chloroquine derivative, onmultidrug resistance in doxorubicin-resistant breast cancer cell line MCF/DOX. J Clin Oncol 7(11):647-649.
41. Zhang Y, Qu X-J, Liu Y, Yang X-H, Hou K-Z, Teng Y-E, Zhang J-D. 2009. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR. Chin J Cancer 28(2):97-99.